In addition to NSCLC and certain types of lymphomas, ALK-EML4 fusions have been reported in inflammatory myofibroblastic tumors, papillary thyroid cancer, breast cancer, and colorectal cancer [21,22,23]. Here, EML4 is linked to breast cancer.